根据ESI于2024年11月发布的数据，我校高被引论文（Highly Cited Papers）505篇，热点论文（Hot Papers）17篇，见附件：2024年11月南方医科大学高被引论文及热点论文简表。详情如下。
从学科角度看，在505篇高被引论文中，临床医学最多（248篇），占比49.11%，分子生物学与遗传学46篇（9.11%）紧跟其后。
|
序号 |
高被引论文 Research Field |
2024.11 |
2024.09 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
1 |
CLINICAL MEDICINE |
248 |
49.11% |
239 |
49.38% |
|
2 |
MOLECULAR BIOLOGY & GENETICS |
46 |
9.11% |
43 |
8.88% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
37 |
7.33% |
37 |
7.64% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
39 |
7.72% |
36 |
7.44% |
|
5 |
MATERIALS SCIENCE |
30 |
5.94% |
33 |
6.82% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
15 |
2.97% |
14 |
2.89% |
|
7 |
ENGINEERING |
10 |
1.98% |
8 |
1.65% |
|
8 |
MICROBIOLOGY |
11 |
2.18% |
10 |
2.07% |
|
9 |
CHEMISTRY |
8 |
1.58% |
5 |
1.03% |
|
10 |
PHYSICS |
11 |
2.18% |
10 |
2.07% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
12 |
2.38% |
11 |
2.27% |
|
12 |
IMMUNOLOGY |
11 |
2.18% |
12 |
2.48% |
|
13 |
SOCIAL SCIENCES, GENERAL |
5 |
0.99% |
5 |
1.03% |
|
14 |
COMPUTER SCIENCE |
9 |
1.78% |
9 |
1.86% |
|
15 |
GEOSCIENCES |
1 |
0.20% |
1 |
0.21% |
|
16 |
AGRICULTURAL SCIENCES |
3 |
0.59% |
3 |
0.62% |
|
17 |
MULTIDISCIPLINARY |
1 |
0.20% |
1 |
0.21% |
|
18 |
ENVIRONMENT/ECOLOGY |
6 |
1.19% |
5 |
1.03% |
|
19 |
MATHEMATICS |
2 |
0.40% |
2 |
0.41% |
|
20 |
合计 |
505 |
100.00% |
484 |
100.00% |
|
序号 |
2024年11月我校17篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
TRIAL OF ENDOVASCULAR THERAPY FOR ACUTE ISCHEMIC STROKE WITH LARGE INFARCT |
NEW ENGLAND JOURNAL OF MEDICINE 388 (14): 1272-1283 APR 6 2023 |
10.1056/NEJMoa2213379 |
CLINICAL MEDICINE |
280 |
|
2 |
MINIMAL INFORMATION FOR STUDIES OF EXTRACELLULAR VESICLES (MISEV2023): FROM BASIC TO ADVANCED APPROACHES |
JOURNAL OF EXTRACELLULAR VESICLES 13 (2): - FEB 2024 |
10.1002/jev2.12404 |
BIOLOGY & BIOCHEMISTRY |
272 |
|
3 |
ASSOCIATION BETWEEN GUT MICROBIOTA AND PREECLAMPSIA-ECLAMPSIA: A TWO-SAMPLE MENDELIAN RANDOMIZATION STUDY |
BMC MEDICINE 20 (1): - NOV 15 2022 |
10.1186/s12916-022-02657-x |
CLINICAL MEDICINE |
177 |
|
4 |
ESTIMATED BURDEN OF STROKE IN CHINA IN 2020 |
JAMA NETWORK OPEN 6 (3): - MAR 2023 |
10.1001/jamanetworkopen.2023.1455 |
CLINICAL MEDICINE |
158 |
|
5 |
OVERALL SURVIVAL WITH OSIMERTINIB IN RESECTED <I>EGFR</I>-MUTATED NSCLC |
NEW ENGLAND JOURNAL OF MEDICINE 389 (2): 137-147 JUL 13 2023 |
10.1056/NEJMoa2304594 |
CLINICAL MEDICINE |
145 |
|
6 |
CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY |
LANCET 402 (10408): 1133-1146 SEP 30 2023 |
10.1016/S0140-6736(23)00961-3 |
CLINICAL MEDICINE |
134 |
|
7 |
BIOMARKERS OF AGING |
SCIENCE CHINA-LIFE SCIENCES : - APR 11 2023 |
10.1007/s11427-023-2305-0 |
BIOLOGY & BIOCHEMISTRY |
93 |
|
8 |
GUIDELINES FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS B (VERSION 2022) |
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY 11 (6): 1425-1442 NOV 2023 |
10.14218/JCTH.2023.00320 |
CLINICAL MEDICINE |
80 |
|
9 |
CRISPR-CAS13A-POWERED ELECTROCHEMICAL BIOSENSOR FOR THE DETECTION OF THE L452R MUTATION IN CLINICAL SAMPLES OF SARS-COV-2 VARIANTS |
JOURNAL OF NANOBIOTECHNOLOGY 21 (1): - APR 29 2023 |
10.1186/s12951-023-01903-5 |
BIOLOGY & BIOCHEMISTRY |
77 |
|
10 |
AGGREGATION-INDUCED EMISSION (AIE), LIFE AND HEALTH |
ACS NANO 17 (15): 14347-14405 JUL 24 2023 |
10.1021/acsnano.3c03925 |
MATERIALS SCIENCE |
77 |
|
11 |
REGULATION OF CISPLATIN RESISTANCE IN BLADDER CANCER BY EPIGENETIC MECHANISMS |
DRUG RESISTANCE UPDATES 68: - MAY 2023 |
10.1016/j.drup.2023.100938 |
PHARMACOLOGY & TOXICOLOGY |
48 |
|
12 |
HERTHENA-LUNG01, A PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED NON-SMALL-CELL LUNG CANCER AFTER EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY AND PLATINUM-BASED CHEMOTHERAPY |
JOURNAL OF CLINICAL ONCOLOGY 41 (35): 5363-+ DEC 10 2023 |
10.1200/JCO.23.01476 |
CLINICAL MEDICINE |
37 |
|
13 |
EVALUATION AND TREATMENT OF KNEE PAIN A REVIEW |
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 330 (16): 1568-1580 OCT 24 2023 |
10.1001/jama.2023.19675 |
CLINICAL MEDICINE |
32 |
|
14 |
ALECTINIB IN RESECTED <I>ALK</I>-POSITIVE NON-SMALL-CELL LUNG CANCER |
NEW ENGLAND JOURNAL OF MEDICINE 390 (14): 1265-1276 APR 11 2024 |
10.1056/NEJMoa2310532 |
CLINICAL MEDICINE |
21 |
|
15 |
NIVOLUMAB PLUS CHEMOTHERAPY IN EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED METASTATIC NON-SMALL-CELL LUNG CANCER AFTER DISEASE PROGRESSION ON EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS: FINAL RESULTS OF CHECKMATE 722 |
JOURNAL OF CLINICAL ONCOLOGY 42 (11): - APR 10 2024 |
10.1200/JCO.23.01017 |
CLINICAL MEDICINE |
12 |
|
16 |
EFFECT OF REPEATED INTRAVENOUS ESKETAMINE ON ADOLESCENTS WITH MAJOR DEPRESSIVE DISORDER AND SUICIDAL IDEATION: A RANDOMIZED ACTIVE-PLACEBO-CONTROLLED TRIAL |
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY 63 (5): 507-518 MAY 2024 |
10.1016/j.jaac.2023.05.031 |
PSYCHIATRY/PSYCHOLOGY |
11 |
|
17 |
TISLELIZUMAB PLUS PLATINUM AND ETOPOSIDE VERSUS PLACEBO PLUS PLATINUM AND ETOPOSIDE AS FIRST-LINE TREATMENT FOR EXTENSIVE-STAGE SCLC (RATIONALE-312): A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PHASE 3 CLINICAL TRIAL |
JOURNAL OF THORACIC ONCOLOGY 19 (7): 1073-1085 JUL 2024 |
10.1016/j.jtho.2024.03.008 |
CLINICAL MEDICINE |
6 |
